- Home
- IMKTA vs SNDX Comparison
IMKTA vs SNDX Comparison
Compare IMKTA & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMKTA
- SNDX
- Stock Information
- Founded
- IMKTA 1963
- SNDX 2005
- Country
- IMKTA United States
- SNDX United States
- Employees
- IMKTA N/A
- SNDX N/A
- Industry
- IMKTA Food Chains
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- IMKTA Consumer Staples
- SNDX Health Care
- Exchange
- IMKTA Nasdaq
- SNDX Nasdaq
- Market Cap
- IMKTA 1.2B
- SNDX 1.1B
- IPO Year
- IMKTA N/A
- SNDX 2016
- Fundamental
- Price
- IMKTA $66.30
- SNDX $9.24
- Analyst Decision
- IMKTA
- SNDX Strong Buy
- Analyst Count
- IMKTA 0
- SNDX 10
- Target Price
- IMKTA N/A
- SNDX $35.80
- AVG Volume (30 Days)
- IMKTA 114.6K
- SNDX 1.8M
- Earning Date
- IMKTA 08-07-2025
- SNDX 07-31-2025
- Dividend Yield
- IMKTA 1.00%
- SNDX N/A
- EPS Growth
- IMKTA N/A
- SNDX N/A
- EPS
- IMKTA 3.26
- SNDX N/A
- Revenue
- IMKTA $5,410,455,724.00
- SNDX $43,722,000.00
- Revenue This Year
- IMKTA N/A
- SNDX $426.77
- Revenue Next Year
- IMKTA N/A
- SNDX $98.31
- P/E Ratio
- IMKTA $20.26
- SNDX N/A
- Revenue Growth
- IMKTA N/A
- SNDX N/A
- 52 Week Low
- IMKTA $58.92
- SNDX $8.58
- 52 Week High
- IMKTA $82.01
- SNDX $25.07
- Technical
- Relative Strength Index (RSI)
- IMKTA 65.38
- SNDX 44.19
- Support Level
- IMKTA $65.44
- SNDX $8.59
- Resistance Level
- IMKTA $66.64
- SNDX $9.50
- Average True Range (ATR)
- IMKTA 1.38
- SNDX 0.53
- MACD
- IMKTA 0.42
- SNDX 0.01
- Stochastic Oscillator
- IMKTA 88.14
- SNDX 47.29
About IMKTA Ingles Markets Incorporated
Ingles Markets Inc is a U.S.-based company that is principally engaged in operating a supermarket chain. The company operates the business in the southeast United States, mainly in Georgia, North Carolina, South Carolina, and Tennessee, with a few stores in Virginia and Alabama as well. The company locates its stores majorly in suburban areas, small towns, and neighborhood areas. It offers a broad range of goods, including food products, pharmacies, health and beauty care products, and general merchandise. The retail business contributes the majority of the company's revenue. The company's real estate ownership of a material portion of total stores enables it to generate rental income.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. Its product candidates include revumenib and axatilimab. It is developing revumenib, a selective menin-MLL inhibitor for KMT2A-rearranged (MLL-r) and NPM1-mutant acute leukemias, including ALL and AML. It is also developing axatilimab, a CSF-1R-blocking antibody for cGVHD and idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells. The business activity of the group is functioned through the region of the United States.